Sanofi (NYSE:SNY) said at the start of April that it promoted Bill Sibold to exec VP of Sanofi Genzyme, effective July 1, 2017. Sibold succeeds Dr. David Meeker, who is slated to leave the company at the end of June. Sibold is the head of Sanofi Genzyme’s global multiple sclerosis, oncology and immunology organization. He […]
Pulmatrix Inc.
Pulmatrix jumps 8% on rumors of potential Mylan takeover bid
Shares in Pulmatrix (NSDQ:PULM) jumped more than 8% today on rumors that the company’s collaboration partner Mylan (NSDQ:MYL) may be interested in a takeover bid. In 2015, the 2 companies inked an ex-U.S. development deal for PUR0200, Pulmatrix’s investigational bronchodilator for the treatment of chronic obstructive pulmonary disease. Mylan had an option on the rights […]
Pulmatrix shares droop on growing losses in FY2016 earnings report
Shares in Pulmatrix (NSDQ:PULM) fell today after the medical device maker posted earnings that showed losses growing while revenue shrunk compared with the prior year. The Lexington, Mass.-based company posted losses of $27.8 million, or $1.88 per share, on sales of $835,000 for the full year, with losses growing 6.4% while revenue shrunk 30.5% when compared […]
Pulmatrix updates on $3m offering
Pulmatrix (NSDQ:PULM) today updated pricing on an upcoming $3.3 million offering, looking to float 950,000 shares at $3.50 per share. The company said it expects to collect $3.1 million after paying for placement agent fees, which it calculated at $216,125. Get the full story at our sister site, Drug Delivery Business News.
Pulmatrix raises $3m in direct offering
Pulmatrix (NSDQ:PULM) said today that unnamed institutional investors agreed to purchase approximately $3.3 million of shares of common stock in a direct offering. The company said it plans to sell 950,000 shares at $3.50 apiece. Pulmatrix expects the offering, which will close next week, to bring in $3.0 million in proceeds to use for general […]
Pulmatrix seeks to raise $5m in direct offering
Pulmatrix (NSDQ:PULM) said today that it landed an agreement with several institutional investors to purchase $5.0 million of shares of common stock in a registered direct offering. The Lexington, Mass.-based company agreed to sell 2 million shares of common stock at $2.50 apiece. The offering is expected to close on Feb. 2. Pulmatrix said it […]
Pulmatrix shares soar after winning FDA designation
Pulmatrix (NSDQ:PULM) shares were up 159% to $1.79 apiece in mid-afternoon trading today after the company announced that its drug candidate for treating fungal infections in the lungs of cystric fibrosis patients was designated as a ‘qualified infectious disease product’ by the FDA. With the designation, the Lexington, Mass.-based company will receive 5 years of […]
Pulmatrix reports Q3 loss, revenue down 91%
Shares in Pulmatrix (NSDQ:PULM) rose slightly after the biotechnology company released its 3rd quarter results. The Lexington, Mass.-based company reeled in its losses 35% to $3.2 million compared to a $4.9 million loss in Q3 last year. Revenue fell 91% compared with the same period last year to $61,000 for the 3 months ended September 30, 2016. Losses per […]
Pulmatrix lands $5.7 million grant from Uncle Sam
Pulmatrix Inc. landed a $5.7 million contract from the Defense Advanced Research Projects Agency to develop a drug/device combination aimed at protecting military personnel and civilians against biological weapons.
DARPA selected the Lexington, Mass.-based company as part of its “7-day Biodefense Initiative,” a project to develop inhaled therapeutics for respiratory infections caused by airborne agents.